- follow-up
- an Event in Toronto January 26
- first personalized medicine data generated by the SAEC
- plus a big boost for comparative effectiveness in the U.S. stimulus bill
- a new algorithm for personalized warfarin dosing
- Standard of Care in Tumor Genotyping
- Comparative Effectiveness Meets Personalized Medicine in the Senate
- new clinical data from the AACR meeting
- CMS decides against Warfarin genetic tests for now
- Figuring out the right time for head-to-head clinical trials
- Companion diagnostics and personalized cancer treatment
- KRAS genotype makes anti-EGFR decisions easier and more cost-effective
- Amgen generates prospective Vectibix data that supports KRAS testing
- Tie goes to the patient
- Dismal data on HER2 testing in the U.S.
- Some skepticism at Merck
- Licensing deal in Montreal puts focus on data analysis
- Personalized Medicine: A Big Market, If We Can Just Figure Out How to Get People to Use It
- The Case for Diagnostics Focuses on Cost and Effectiveness
- Costs Savings from Personalized Medicine Sought by PBMs, Employers, Pharma Face Legal and Privacy Hurdles
11 responses so far ↓
Trends Update — Comparative Effectiveness and Personalized Medicine: Patient-Centered Outcomes Research Act of 2009 Increases Personalized Medicine Focus « The Cross-Border Biotech Blog // June 19, 2009 at 10:24 pm |
[...] takes a close look at the Baucus-Conrad Comparative Effectiveness Bill and notes that the influence of personalized medicine that we’ve flagged as a trend in 2009 has shown up in this year’s verison of the bill [...]
Trends Update — Comparative Effectiveness and Personalized Medicine: Genetic Test Identifies Patient Subpopulation for Benefit, Avoids Wasted Money and Time for Others on Erbitux, Vectibix « The Cross-Border Biotech Blog // July 20, 2009 at 11:05 am |
[...] 20, 2009 · Leave a Comment This is exactly how personalized medicine and comparative effectiveness can interact to benefit patients, pharma companies and [...]
Trends Update — Personalized Medicine and Comparative Effectiveness: HepC Treatment Gap, Leukaemia Genetics and Beckman Coulter Genomics « The Cross-Border Biotech Blog // August 17, 2009 at 2:21 pm |
[...] August 17, 2009 · Leave a Comment A few interesting items hit the news this morning that continue the trend of explaining comparative effectiveness data by examining underlying genetic variation. [...]
Trends Update — Personalized Medicine: Merck Strategy Head Skeptical « The Cross-Border Biotech Blog // September 23, 2009 at 9:03 am |
[...] 23, 2009 · Leave a Comment As I’ve been following personalized medicine on this blog, I have become almost convinced that recent advances in genomics technology put us at the brink of [...]
Jeremy Grushcow’s Article Appears in Counsel to Counsel Magazine’s Life Sciences Feature « The Cross-Border Biotech Blog // September 29, 2009 at 6:32 pm |
[...] September 29, 2009 · Leave a Comment A blurb by Jeremy on “Comparative Effectiveness and Personalized Medicine” was included in the September/October issue of Counsel to Counsel Magazine. For more, stay tuned to this blog’s Trends in 2009 page on the topic. [...]